Papers
2
Total Citations
55
H-Index
2
About
Paul Davies is a leading figure in the development of high-throughput drug discovery platforms, with a specialized focus on deubiquitylating enzymes (DUBs) and their role in cancer biology. His most impactful work centers on pioneering a novel, high-throughput matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based assay for DUB activity, a breakthrough that has garnered 49 citations. This methodology enables the rapid, sensitive, and label-free screening of DUB inhibitors, addressing a critical bottleneck in the field of ubiquitin-proteasome system therapeutics. By adapting MALDI-TOF, traditionally used for proteomics, to a functional enzymatic assay, Davies has provided the drug discovery community with a powerful tool for identifying novel modulators of protein degradation pathways. His contributions are particularly significant given the growing interest in DUBs as therapeutic targets for cancers and neurodegenerative diseases. Davies’ work exemplifies the translation of advanced analytical chemistry into practical, high-impact screening solutions, positioning him as a key innovator at the intersection of mass spectrometry and chemical biology.
Research Focus
Key Achievements
Top Papers
- 1
- 2